Menu Search
Equities

Smith & Nephew PLC

SN.:LSE

Smith & Nephew PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)1,162.50
  • Today's Change-13.50 / -1.15%
  • Shares traded2.33m
  • 1 Year change+10.87%
  • Beta0.9550
Data delayed at least 20 minutes, as of Sep 18 2024 16:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform9
Hold5
Sell0
Strong Sell0

Share price forecast in USD

The 16 analysts offering 12 month price targets for Smith & Nephew plc have a median target of 1,377.55, with a high estimate of 1,486.21 and a low estimate of 1,080.46. The median estimate represents a 18.50% increase from the last price of 1,162.50.
High27.8%1,486.21
Med18.5%1,377.55
Low-7.1%1,080.46

Dividends in USD

In 2023, Smith & Nephew PLC reported a dividend of 0.39 USD, which represents a 2.16% increase over last year. The 18 analysts covering the company expect dividends of 0.37 USD for the upcoming fiscal year, a decrease of 3.55%.
Div growth (TTM)2.16%
More ▼

Earnings history & estimates in USD

On Feb 05, 2015, earnings of 0.26 per share. This result was in line with the consensus of the 4 analysts following the company
The next earnings announcement is expected on Feb 24, 2025.
Average growth rate+5.12%
Smith & Nephew plc reported annual 2023 earnings of 0.828 per share on Feb 27, 2024.
Average growth rate-2.36%
More ▼

Revenue history & estimates in USD

Smith & Nephew plc had 2nd quarter 2024 revenues of 1.44bn. This missed the 1.45bn consensus estimate of the 3 analysts following the company. This was 6.27% above the prior year's 2nd quarter results.
Average growth rate+1.24%
Smith & Nephew plc had revenues for the full year 2023 of 5.55bn. This was 6.40% above the prior year's results.
Average growth rate+2.38%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.